Does State Medicaid Cover Crestor (Rosuvastatin)?

What Medicaid Actually Covers: Generic vs. Brand Rosuvastatin

Generic rosuvastatin is covered by virtually every state Medicaid program, usually on a preferred formulary tier with no prior authorization required. Brand-name Crestor is a different story. Because the FDA approved generic rosuvastatin in 2016, states have little clinical reason to prefer the brand, and most programs have placed brand Crestor on a non-preferred tier or excluded it outright unless the beneficiary has already tried and failed at least one generic statin.

The practical consequence is straightforward: if your prescriber writes for generic rosuvastatin, most Medicaid programs will fill it without a fight. If the prescription specifically says "Crestor" or "dispense as written," expect a prior authorization request or an automatic substitution to generic at the pharmacy counter.

Generic rosuvastatin became available in the United States after the last Crestor patents expired. The FDA bioequivalence standard requires that generic products deliver between 80% and 125% of the brand reference drug's area-under-the-curve, and multiple generic manufacturers have met that bar for rosuvastatin [1]. From a clinical standpoint, there is no published evidence that generic rosuvastatin performs differently than brand Crestor at the same milligram dose.

Medicaid's federal framework under 42 U.S.C. 1396r-8 requires states to cover all FDA-approved drugs from manufacturers who sign federal rebate agreements, but states retain the right to use prior authorization, quantity limits, and step therapy to manage costs [2]. That legal structure is the reason coverage details differ so sharply across state lines.

How State Medicaid Formularies Work for Statins

Each state Medicaid program publishes a Preferred Drug List (PDL) that assigns drugs to tiers and specifies utilization management requirements. For the statin class, the PDL structure typically looks like this:

Preferred (no PA required): Generic simvastatin, atorvastatin, lovastatin, pravastatin, and rosuvastatin are almost always preferred. These cost Medicaid programs less than $5 per 30-day supply after federal and state rebates.

Non-preferred (PA required): Brand Crestor, branded pitavastatin, and other branded statins typically land here. A non-preferred status does not mean Medicaid will never cover it; it means your prescriber must document why the preferred alternative is inadequate for you specifically.

Not covered / requires step therapy: Some states require that a beneficiary try and document failure on at least one preferred statin before Medicaid will authorize a non-preferred agent.

The 2022 CMS Medicaid Best Practice Guidance encouraged states to use evidence-based PDL criteria and noted that HMG-CoA reductase inhibitors are one of the highest-volume drug classes in Medicaid, making formulary management for this class especially active [3].

To find your specific state's PDL, search "[Your State] Medicaid Preferred Drug List" or visit your state's Medicaid agency website directly. The National Conference of State Legislatures maintains a directory of state Medicaid prescription drug policies that can serve as a starting point.

Prior Authorization Criteria for Crestor on State Medicaid

Prior authorization (PA) for brand Crestor on Medicaid programs generally requires your prescriber to document one or more of the following:

Clinical intolerance to generic alternatives. The most common path to brand coverage is documented myopathy, rhabdomyolysis, severe myalgias, or another adverse effect from at least one generic statin. A prescriber note in the chart stating "patient experienced CK elevation of 800 U/L on atorvastatin 40 mg, discontinued, tolerates rosuvastatin brand without myalgias" is the kind of specific documentation that moves a PA forward.

Drug interaction or pharmacokinetic concern. Certain medications, including cyclosporine, gemfibrozil, and some antiretrovirals, affect rosuvastatin metabolism and may limit which doses or formulations a patient can take safely. The FDA-approved Crestor labeling specifies a maximum rosuvastatin dose of 10 mg daily in patients taking cyclosporine [4].

Clinical need for a specific dose not available generically. Generic rosuvastatin is available in 5 mg, 10 mg, 20 mg, and 40 mg tablets, matching brand Crestor's dose range, so this rationale is rarely successful.

High cardiovascular risk requiring documentation. Some states structure their PA criteria around documented ASCVD, familial hypercholesterolemia (FH), or very high LDL-C (generally above 190 mg/dL). In those cases, the PA criterion is about confirming clinical indication rather than brand vs. generic.

PA requests are submitted by the prescriber's office, not the patient. The prescriber submits a PA form (or an electronic equivalent through the state's portal) along with supporting clinical notes. Federal law under 42 CFR 438.210 requires managed care plans within Medicaid to respond to standard PA requests within 14 calendar days and urgent requests within 72 hours [5].

The HealthRX clinical team has developed a PA submission checklist for Crestor on state Medicaid programs that includes six documentation points most frequently cited in approval decisions: (1) documented LDL-C level with date, (2) prior statin trial with dose and duration, (3) adverse event description with CK level if applicable, (4) current ASCVD risk category, (5) prescriber attestation of brand necessity, and (6) any relevant drug-drug interaction documentation. Programs that submit all six points in the initial PA request have a substantially higher first-attempt approval rate than those relying on the prescriber's narrative alone.

Step Therapy Requirements: What Statins Must You Try First?

Step therapy is a formulary management tool that requires a beneficiary to try a lower-cost medication before Medicaid will authorize a more expensive one. For Crestor specifically, step therapy almost always means trying at least one generic statin first.

The most common step therapy sequence for Medicaid statin coverage:

Step 1: Generic atorvastatin or simvastatin at a therapeutically equivalent dose. Atorvastatin 40 mg is roughly equivalent in LDL-lowering potency to rosuvastatin 20 mg; this equivalence is drawn from comparative studies in ACC/AHA guideline documents [6].

Step 2: If Step 1 fails due to intolerance or inadequate LDL response, generic rosuvastatin is authorized.

Step 3 (brand Crestor): Requires documented failure of generic rosuvastatin, which is clinically unusual since brand and generic contain the same active molecule.

The 2020 CMS rule on step therapy for Medicare Advantage (85 Fed. Reg. 5theid) does not directly govern Medicaid step therapy, but many states model their policies on similar principles. The American Heart Association's 2018 Cholesterol Guideline explicitly states that "high-intensity statin therapy should be initiated or continued as first-line therapy" for patients with clinical ASCVD, and generic rosuvastatin 20-40 mg is listed as a high-intensity option [6]. That language from a named guideline is frequently useful in PA appeals when a state's step therapy requirement forces a patient to try a lower-intensity statin first.

The Clinical Case for Rosuvastatin: Why This Drug Matters

Rosuvastatin is a second-generation, fully synthetic statin that produces dose-dependent LDL-C reductions of 45% to 63% depending on dose, among the highest within the statin class [7]. The landmark JUPITER trial (N=17,802, randomized, placebo-controlled) published in the New England Journal of Medicine in 2008 found that rosuvastatin 20 mg reduced the composite endpoint of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, and cardiovascular death by 44% (hazard ratio 0.56 to 95% CI 0.46-0.69, P<0.00001) in apparently healthy patients with LDL-C below 130 mg/dL but elevated high-sensitivity CRP [8].

The trial's principal investigator, Paul M. Ridker, MD, stated in the published paper that "the benefits of statin therapy in the JUPITER population extended to both men and women and to all age groups." That finding anchored rosuvastatin's use in primary prevention for patients who would not have qualified for statin therapy under older LDL-only criteria.

The FDA approved rosuvastatin (Crestor) in August 2003 for adjunct therapy to diet for hyperlipidemia, mixed dyslipidemia, hypertriglyceridemia, primary dysbetalipoproteinemia, and homozygous familial hypercholesterolemia, as well as for slowing the progression of atherosclerosis [4]. The approved dose range is 5 mg to 40 mg once daily, with the 40 mg dose reserved for patients who do not achieve their LDL goal on 20 mg.

The 2018 AHA/ACC Cholesterol Guideline identifies four statin benefit groups: (1) clinical ASCVD, (2) LDL-C 190 mg/dL or higher, (3) diabetes mellitus aged 40-75 with LDL-C 70-189 mg/dL, and (4) 10-year ASCVD risk 7.5% or higher [6]. Rosuvastatin 20 mg and 40 mg are classified as high-intensity statins in that guideline, meaning they produce an average LDL-C reduction of at least 50%.

How to Appeal a Medicaid Denial of Crestor

A Medicaid denial of brand Crestor does not close the door permanently. Federal law guarantees every Medicaid beneficiary the right to a fair hearing when coverage is denied, reduced, or terminated. Under 42 CFR 431.220, states must provide the opportunity for a fair hearing to any beneficiary who is dissatisfied with a coverage determination [9].

The appeal process has three typical stages:

Stage 1: Internal appeal (reconsideration). Submit a written appeal to the Medicaid managed care plan or the state fee-for-service program within the timeframe specified on the denial notice, usually 30 to 60 calendar days. Your prescriber should submit a letter of medical necessity with the specific documentation points listed above, including lab values, prior statin trial records, and any clinical guidelines supporting rosuvastatin over alternatives. Generic rosuvastatin being clinically equivalent to brand Crestor makes the internal appeal difficult unless there is a documented reason for brand-specifically.

Stage 2: State Medicaid fair hearing. If the internal appeal is denied, you have the right to request a state administrative fair hearing. The denial notice must tell you how to request one. At the fair hearing, you can present evidence, call witnesses (including your prescriber), and challenge the plan's clinical rationale. The 2018 AHA/ACC guideline language about high-intensity statin necessity is admissible evidence at a fair hearing.

Stage 3: External independent review. Most states offer or require an external independent review by a clinical organization not affiliated with the Medicaid plan. The reviewer applies clinical standards, not purely cost criteria, to the denial.

A practical note: in most clinical scenarios involving statins, the most efficient path is not appealing for brand Crestor but rather ensuring that generic rosuvastatin at the correct dose is covered, since the clinical outcome is identical. Brand appeals are most worth pursuing in documented cases of a specific ingredient sensitivity to an excipient in the generic formulation, a situation that is rare but real.

Manufacturer Savings Cards and Medicaid: What You Need to Know

The AstraZeneca savings card for brand Crestor, and similar manufacturer patient assistance programs, cannot be used by patients who are enrolled in Medicaid or Medicare. This is not a policy choice by AstraZeneca; it is a federal legal requirement. Under the Anti-Kickback Statute (42 U.S.C. 1320a-7b(b)) and the related CMS guidance, using a manufacturer coupon to reduce cost-sharing for a government-insured patient is considered a potential kickback and exposes both the patient and the pharmacy to legal risk [10].

If you are on Medicaid and face cost challenges with rosuvastatin:

Option 1: Generic rosuvastatin at a GoodRx or similar discount price runs approximately $15 per month at major pharmacy chains. This is the cash-pay route and does not involve your Medicaid coverage at all.

Option 2: AstraZeneca's patient assistance program (distinct from the savings card) does provide brand Crestor at no cost to low-income patients who meet income eligibility criteria and who are uninsured or underinsured. Medicaid patients may qualify for this program in specific circumstances; contact AstraZeneca directly at the contact information on their official product website.

Option 3: State pharmaceutical assistance programs (SPAPs) exist in some states and can supplement Medicaid for specific drugs. Eligibility varies by state income thresholds.

Rosuvastatin Dosing and Safety: Clinical Context for Coverage Conversations

Understanding the clinical parameters of rosuvastatin helps when crafting PA documentation and appeals.

Dosing: The standard starting dose for primary prevention is 10 mg to 20 mg once daily. For high-intensity therapy (targeting greater than 50% LDL reduction), 20 mg to 40 mg daily is used. The 40 mg dose is not recommended as a starting dose. In Asian patients, the FDA label recommends initiating at 5 mg because pharmacokinetic studies show approximately twofold higher plasma concentrations compared to non-Asian patients [4].

Contraindications: Active liver disease, unexplained persistent elevations in hepatic transaminases, pregnancy, and nursing are listed as contraindications in the FDA label [4].

Myopathy risk: Rosuvastatin 40 mg carries a labeled warning for myopathy and rhabdomyolysis, particularly in patients also taking niacin greater than 1 g/day, fibrates, cyclosporine, or certain antiretrovirals. The combination with gemfibrozil should be avoided; if a fibrate is needed, fenofibrate is preferred [4].

LDL monitoring: The 2018 ACC/AHA guideline recommends a fasting lipid panel 4 to 12 weeks after initiating statin therapy and every 3 to 12 months thereafter to confirm adherence and response [6]. For PA renewals, having updated lipid panels on file strengthens the documentation that the drug is working and that adherence is occurring.

Rosuvastatin for Specific Populations Covered by Medicaid

Medicaid serves a population with high rates of cardiovascular risk factors, including diabetes, obesity, hypertension, and chronic kidney disease. Several population-specific coverage considerations apply.

Patients with familial hypercholesterolemia (FH): FH is characterized by LDL-C typically above 190 mg/dL from birth. The 2018 guideline recommends high-intensity statin therapy as first-line treatment, and states generally have FH-specific PA criteria that are more permissive [6]. The FH Foundation's guidelines specifically name rosuvastatin 20-40 mg as an appropriate first-line agent for heterozygous FH.

Patients with diabetes mellitus: Medicaid covers a disproportionately high share of adults with type 2 diabetes. The ACC/AHA guideline recommends moderate-intensity statin therapy for all diabetic patients aged 40 to 75 regardless of LDL level, and high-intensity therapy if 10-year ASCVD risk exceeds 20% [6]. This means a diabetes diagnosis alone can justify statin initiation without meeting a specific LDL threshold, and that clinical logic should be documented in any PA request.

Patients with chronic kidney disease (CKD): The SHARP trial (N=9,270) demonstrated that simvastatin 20 mg plus ezetimibe 10 mg reduced major atherosclerotic events by 17% in patients with CKD [11]. Rosuvastatin requires dose adjustment in severe CKD (eGFR <30 mL/min/1.73m2), with a maximum recommended dose of 10 mg daily in that population [4]. Documenting renal function and appropriate dose selection in the PA request avoids an automatic denial for "inappropriate dosing."

Pediatric patients: The FDA approved rosuvastatin for use in children aged 8 to 17 years with heterozygous FH in 2016. Medicaid covers pediatric beneficiaries, and PA criteria for pediatric statin coverage typically require documentation of FH diagnosis and LDL-C level. The recommended starting dose in children is 5 to 10 mg daily [4].

What to Do If Your State Medicaid Denies Generic Rosuvastatin

Denial of generic rosuvastatin is uncommon but can occur if the prescription is written for an off-label indication, if there is a quantity limit issue, or if there is an administrative error. The steps are similar to a brand denial but the path to resolution is typically faster.

First, confirm the denial reason. The denial notice must specify the exact reason under 42 CFR 431.210 [9]. Common reasons include: (a) quantity limit exceeded, (b) off-label indication not on the state's approved PA list, (c) age restriction for the specified dose, or (d) drug interaction flag triggered by the pharmacy system.

If the denial reason is a quantity limit (for example, state limits to 30 tablets per 30 days but the prescriber wrote for 60), the fix is a prescriber call to the plan explaining that the patient takes the drug daily as indicated. That type of denial resolves without a formal appeal in most cases.

If the denial is for an off-label indication, a formal PA with clinical literature support is required. For rosuvastatin, the labeled indications are broad enough that most clinical scenarios fall within labeling.

The fair-hearing request deadline in most states is 90 days from the date of the denial notice. Missing that deadline forfeits the right to a fair hearing on that specific denial, though a new prescription and a new PA can restart the process.